We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NANOTECH FIRM SEES CUTTING-EDGE DIAGNOSTICS AS KEY IN 'PERSONALIZED MEDICINE' TREND

NANOTECH FIRM SEES CUTTING-EDGE DIAGNOSTICS AS KEY IN 'PERSONALIZED MEDICINE' TREND

June 1, 2006

Using nanotechnology in the device and pharmaceutical industries is such a new concept that the FDA hasn't even figured out how to regulate it yet.

But the future looks bright for nanotechnology to play a key role in improving diagnostics methods to advance a new generation of biotechnology drugs, according to Nanosphere, a Northbroook, Ill.-based life science company.

Current diagnostic systems rely on complex, expensive, lab-based technology requiring relatively large samples that run the risk of cross-contamination, the company says. Nanosphere's goal is to simplify genetic testing and make it less expensive to conduct, which should allow hospital lab technicians to use the technology rather than confining the process to specialists.

Nanosphere is currently seeking FDA approval for its Verigene System -- a device that uses nanoparticles to detect minute quantities of nucleic acids and proteins.

The technology uses ultra-sensitive protein detection methods, or "biobarcodes," to identify biomarkers -- physical traits that point to the early presence of disease. The company intends to use a recent $57 million financing deal to commercialize Verigene.

As part of its efforts to develop and market products to detect and treat difficult-to-cure diseases at their earliest stages, the company has teamed with Applied NeuroSolutions to identify new diagnostics for Alzheimer's Disease.

The collaboration combines Nanosphere's biobarcodes and Applied NeuroSolutions biomarkers, which "have been shown to be 85 to 95 percent accurate in the detection of Alzheimer's disease," according to findings published in the Annals of Neurology, Journal of Internal Medicine, American Journal of Psychiatry, and other publications.

(http://www.fdanews.com/ddl/33_22/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing